PM — Philip Morris International Inc.

Summary of Philip Morris International (PM) Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Adjusted Diluted EPS: Increased by 17% to a record $2.24.
• Adjusted Operating Income (OI): Grew by 7.5% organically and 12.4% in dollar terms to $4.7 billion.
• Organic Net Revenue Growth: Up 5.9%, or 7.3% excluding the Indonesia technical impact.
• Smoke-Free Gross Profit: Exceeded $3 billion for the first time, with a gross margin of 70%.
• Total Shipment Volume: Increased by 0.7% in Q3, with smoke-free volume growth of 16.6%.
• Cigarette Volumes: Declined by 3.2%, aligning with the forecasted decline of 3% to 4% for H2.

2. Strategic Updates and Business Highlights

• Smoke-Free Business Performance: Strong growth for flagship brands IQOS, ZYN, and VIVE, outpacing the global smoke-free industry.
• Geographic Expansion: Smoke-free products are now available in 100 markets, with recent launches including IQOS in Taiwan.
• Multi-Category Strategy: All smoke-free brands are commercialized together in 25 markets, enhancing growth.
• U.S. Market Dynamics: ZYN saw significant growth, with shipments increasing by 37% in Q3, supported by a promotional campaign targeting legal age nicotine users.

3. Forward Guidance and Outlook

• Full-Year Guidance:
  • Adjusted diluted EPS growth forecast raised to 12-13.5%, translating to 13.5-15.1% in dollar terms.
  • Organic net revenue growth expected at 6-8%, with smoke-free volume growth projected at 12-14%.
  • Anticipated adjusted OI growth of 10-11.5% for the year.
• Q4 Expectations: Continued strong performance anticipated, with an acceleration in smoke-free growth and a focus on aligning shipment volumes with market sales.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: Increased competition in the heated tobacco segment, particularly in Japan, could impact IQOS's market share.
• Promotional Costs: A one-off promotional campaign for ZYN in Q3 resulted in a $100 million reduction in sales, which may affect profitability.
• Inventory Adjustments: Anticipated inventory reductions for ZYN (20-30 million cans) and IQOS (2 billion units) could impact Q4 financials.
• Tax Rate Increase: Expected higher effective tax rate in Q4 compared to the first nine months of the year.

5. Notable Q&A Insights

• ZYN Growth Strategy: Management emphasized the importance of growing the nicotine pouch category and maintaining ZYN's premium positioning despite increased promotional activity.
• IQOS Shipment vs. IMS: There is a noted mismatch between HTU shipments and in-market sales (IMS), with expectations of aligning these metrics in Q4.
• Future Investments: Continued investment in the U.S. market for both ZYN and IQOS is planned, indicating a long-term commitment to growth despite short-term promotional costs.
• FDA Review Process: Management is optimistic about the FDA's plans to streamline the review process for nicotine pouches, which could benefit future product launches.

Overall, PM reported strong financial results driven by its smoke-free product portfolio, while also navigating challenges from competition and promotional costs. The company remains optimistic about future growth, particularly in the U.S. market.